Psoriasis phototherapy expectations by body area

Readers ask whether to use a clinic cabinet or a home unit, and either way the body area shapes what to expect. I read the National Psoriasis Foundation on that. It states that moderate-to-severe psoriasis is not set by body surface area alone. It names the face, scalp, hands, feet, nails and genitals as high-impact sites. Psoriasis on one of those counts as moderate-to-severe too. NICE records assessment across skin, nails, high-impact sites, life impact and joint concerns. The Psoriasis Area and Severity Index splits the body into four scored regions: head, upper limbs, trunk and lower limbs.

I read the two AAD scalp pages. They ask you to lift hair out of the way when applying medicine, and for a salicylic-acid scale softener before scale comes off. Its treatment page records a topical corticosteroid as the most commonly prescribed scalp treatment. That can go on directly, or as a clobetasol propionate medicated shampoo. Scale softeners help medicine reach the skin. It records calcipotriene, tazarotene and coal tar as further options, plus corticosteroid injections and excimer laser in the office.

I read the AAD on narrowband UVB. It records that the light slows the growth of fast-growing skin cells and calms an overactive immune system. It also reduces inflammation and reduces or removes itch. A dermatologist sets the plan and adjusts it. NPF records that the light goes into the skin and slows the growth of affected skin cells. AAD records scale softeners on the scalp so that medicine reaches the skin. A skin of color review reports that added topical treatment changed plaque outcomes.

NPF counts the genitals as a high-impact site. The AAD record I read says strong products on thin skin carry skin-thinning, spider-vein and stretch-mark risk. AAD also records the immediate effects of phototherapy: a sunburn-like reaction, mild stinging or burning, itching, and rare blisters or burns. NPF records redness, stinging and burns, and asks for check-ups under medical supervision. British Association of Dermatologists guidelines record a consent form naming the same clothing at each session.

I went through the separate AAD treatment list for nails. It holds a strong topical corticosteroid, calcipotriol or tazarotene, injections into or near the nail, and systemic medicines for severe skin-and-nail disease. AAD records that laser therapy for nails is under-researched. Results are slow because nails grow slowly, and clearing debris usually takes six months or longer. For the scalp, AAD records excimer laser as a targeted in-office option.

I read the British Association of Dermatologists guidelines. They back UV-protective goggles, and keeping stray UV off people nearby. They record a consent form that names goggles and the same clothing at each session. They also record safety limits including sunburn-type reactions. NPF counts the face among the sites that raise severity on their own. AAD records that strong products on thin facial skin carry skin-thinning, spider-vein and stretch-mark risk.

The systematic review I read pooled nine studies of narrowband UVB for psoriasis in skin of color. They covered roughly 1,334 participants with Fitzpatrick skin types III through V, mostly from Asia. The pooled PASI75 response rate was 70.5%, with a 95% confidence interval of 65% to 75%. It reports hyperpigmentation after treatment in darker skin tones, and notes that harder-to-see redness may leave side effects underreported. AAD records dark spots as more common in medium-to-dark complexions.

The Psoriasis Area and Severity Index already works this way. It scores each region on its own, grading redness, thickness and scale from 0 to 4. The amount of skin involved is graded separately, from 0 to 6. NPF supports a worksheet for daily symptoms and their severity, on paper or on a phone. Its care-path page asks you to bring that record, share it, and note changes in severity and affected areas.